君實生物-B(01877.HK):申請內資股於全國中小企業股份轉讓系統終止掛牌獲股東批准
格隆匯4月8日丨君實生物-B(01877.HK)公佈,有關全國中小企業股份轉讓系統終止掛牌、授權董事會辦理有關全國中小企業股份轉讓系統終止掛牌事宜,以及保護措施的全國中小企業股份轉讓系統終止掛牌決議案,已於2020年第一次臨時股東大會上分別以特別決議案獲股東批准。代表363,753,736股內資股及50,990,669股H股的股東(或其委任代表)出席2020年第一次臨時股東大會當中,合共414,723,805股股份(佔出席已發行股份總數約99.995%)投票贊成及20,600股股份(佔出席已發行股份總數約0.005%)投票反對全國中小企業股份轉讓系統終止掛牌決議案。
於2020年第一次臨時股東大會日期及公告日期,公司已發行股份數目為784,146,500股(包括601,400,000股內資股及182,746,500股H股)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.